

**Amendments to the Claims**

Please amend claims 1-4, 6, and 7 as follows.  
This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1. (Currently Amended) An isolated human antibody that binds to human epidermal growth factor receptor (EGF-r), ~~that wherein said antibody is characterized by the following functions:~~

Inhibits tyrosine phosphorylation of EGF-r;  
Is internalized with EGF-r;  
Inhibits the degradation of EGF-r; and  
Inhibits the EGF induced degradation of EGF-r.

2. (Currently Amended) An isolated human antibody that binds to human epidermal growth factor receptor, ~~that wherein said antibody is characterized by the following functions:~~ Protects protects threonine ~~phosphorylation~~ phosphorylation of EGF-r.

3. (Currently Amended) An isolated human antibody that binds to human epidermal growth factor receptor, ~~that wherein said antibody is characterized by the following functions:~~ Protects protects threonine phosphorylation of a 63 KD protein.

4. (Currently Amended) An isolated human antibody that binds to human epidermal growth factor receptor,

~~that wherein said antibody is characterized by the following functions:~~

Inhibits VEGF production by tumor cells by greater than 50%; and  
Inhibits VEGF production by endothelial cells by greater than 40%.

5. (Original) The antibody of Claim 4, wherein the tumor cells are A431 cells.

6. (Currently Amended) The antibody of Claim 4, wherein the ~~tumor~~ endothelial cells are ECV304 cells.

7. (Currently Amended) An isolated human antibody that binds to human epidermal growth factor receptor, ~~that wherein said antibody is characterized by the following functions:~~

Inhibits tyrosine phosphorylation of EGF-r;  
Is internalized with EGF-r;  
Inhibits the degradation of EGF-r;  
Inhibits the EGF induced degradation of EGF-r;  
Protects threonine ~~phosphorylation~~ phosphorylation of EGF-r;  
Protects threonine phosphorylation of a 63 KD protein;  
Inhibits VEGF production by tumor cells by greater than 50%; and  
Inhibits VEGF production by endothelial cells by greater than 40%.